Elegen
Elegen is a DNA Synthesis & Biofoundries company founded in 2017 and based in San Carlos, United States.
Elegen, founded in 2017 and based in San Carlos, California, uses a proprietary cell-free, microfluidics-based approach to assemble long, high-accuracy synthetic DNA on a faster timeline than cloning-based methods. Its ENFINIA DNA product line delivers clonal-quality genes—and GMP-grade DNA for clinical genetic-medicine development—turning around long constructs in days. In May 2024 the company raised a $35 million Series B led by Triatomic Capital, with strategic participation from GSK, which licensed Elegen's technology for vaccine and medicine development. Founder Matthew Hill leads the company as CEO.
Its cell-free, days-fast production of long accurate DNA targets the speed bottleneck in gene synthesis, and its push into GMP-grade material aims squarely at the genetic-medicine supply chain.
elegenbio.com ↗·DNA Synthesis & Biofoundries·
United States·private 
